ResMed share price higher on Q3 'solid beat'

ResMed had a stronger than expected third quarter and has impressed the market.

| More on:
A man sees some good news on his phone and gives a little cheer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • ResMed shares are on the move on Friday morning
  • The sleep treatment company released a strong third-quarter update today
  • ResMed beat the market's expectations on both the top and bottom line

The ResMed Inc. (ASX: RMD) share price is on course to end the week on a positive note.

In morning trade, the sleep treatment company's shares are up 1% to $34.19.

Why is the ResMed share price rising?

Investors have been bidding the ResMed share price higher today after the company released its third-quarter update.

For the three months ended 31 March, ResMed reported a 29% (31% in constant currency) increase in revenue over the prior corresponding period to US$1,116.9 million.

And while its gross margin contracted by 150 basis points to 55.3%, this couldn't stop the company from delivering a 28% increase in income from operations.

This ultimately led ResMed generating operating cash flow of US$282.6 million and diluted earnings per share of US$1.58.

What were the drivers of its growth?

Management revealed that it significantly ramped up production and delivery of its cloud-connected flow generator devices to meet ongoing high demand from customers during the quarter. This resulted in strong device sales growth across its global markets. ResMed CEO, Mick Farrell, commented:

We now have full global availability of our connected AirSense 10 platform, while we continue to ramp production and availability across more geographies of our AirSense 11 platform. The bottom line is this: We can now support global customer demand for CPAP and APAP devices to serve the entire sleep device market. This is great news for physicians, providers, and especially for patients.

Farrell also revealed that its mask and patient interfaces businesses performed well, as did its outside-hospital software-as-a-service business. He added:

We also saw very strong growth in our mask and patient interfaces businesses globally, demonstrating a sustainable focus on patient adherence and resupply. Our outside-hospital software-as-a-service business achieved high-single-digit growth organically and reached well into double-digit growth with a full quarter of contribution from our MEDIFOX DAN acquisition that we closed last November.

How does this compare to expectations?

Goldman Sachs has taken a quick look at the result and notes that the company's revenue growth was comfortable ahead of expectations. This may explain why the ResMed share price is rising as it is today. The broker said:

3Q23 revenue of $1,117m was up +31% cc, an acceleration from +20% in 2Q and +9% in 1Q23, and a solid beat to consensus +23%.

Pleasingly, it was the same for the company's earnings, with ResMed beating on the bottom line. Goldman adds:

Earnings beat +3% as revenue growth compensates for material gross margin contraction.

Goldman currently has a buy rating and $38.00 price target on ResMed shares.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »